This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Free Online Activities

Managing Weight Gain and Metabolic Issues in Patients Treated With Atypical Antipsychotics

David C. Henderson, MD

Published: February 14, 2008

Article Abstract

The proven efficacy of second-generation antipsychotics (SGA) has led many clinicians to switch patients from a conventional antipsychotic to an SGA. However, SGAs may be associated with weight gain, dyslipidemia, high blood pressure, and ultimately with cardiovascular disease, diabetes, and metabolic syndrome. Clinicians should be aware of patients’ individual risk factors for developing these illnesses and should carefully screen for changes in weight, body mass index, waist size, or lipid levels that could be potentially harmful and increase the risk for a more serious illness.

This CME activity is expired. For more CME activities, visit
Find more articles on this and other psychiatry and CNS topics:
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 69

Quick Links: Metabolic Disorder , Side Effects-Medication


Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...